Lytix Biopharma Feed

2026-10-19 17:39:46 LYTIX: Financial calendar

2026-10-19 17:39:46 LYTIX: Finansiell kalender

2026-09-03 15:02:39 Lytix Biopharma ASA: Grant of share options to management and key personnel 8,40 NOK | +1,20% | 0,14 MNOK

2026-09-02 22:01:37 Lytix Biopharma ASA: Mandatory notification of trade by primary insider 8,40 NOK | +1,20% | 0,14 MNOK

2026-08-27 07:02:00 Lytix Biopharma Q2 2026: Marking Defining Milestone 7,96 NOK | +1,27% | 0,49 MNOK

2026-08-27 07:00:00 Lytix Biopharma Q2 2026: FDA Feedback Clears Path to Registrational Phase III Trial for Ruxotemitide (LTX-315) in Patients with Resectable High-Risk Melanoma, Marking Defining Milestone 7,96 NOK | +1,27% | 0,49 MNOK

2026-08-27 06:57:00 Lytix Biopharma ASA: FDA Feedback Clears Path to Registrational Phase III Trial for Ruxotemitide (LTX-315) in Patients with Resectable High-Risk Melanoma 7,96 NOK | +1,27% | 0,49 MNOK

2026-08-27 06:55:00 LYTIX: FDA Feedback Clears Path to Registrational Phase III Trial for Ruxotemitide (LTX-315) in Patients with Resectable High-Risk Melanoma 7,96 NOK | +1,27% | 0,49 MNOK

2026-08-26 17:43:08 Lytix Biopharma ASA: Lytix to Partner with Leading Investigator on ALETTA Study Testing Ruxotemitide in Combination with Ipilimumab and Nivolumab in Early-stage Resectable Melanoma 7,96 NOK | +1,27% | 0,49 MNOK

2026-08-26 17:01:52 LYTIX: Lytix to Partner with Leading Investigator on ALETTA Study Testing Ruxotemitide in Combination with Ipilimumab and Nivolumab in Early-stage Resectable Melanoma 7,96 NOK | +1,27% | 0,49 MNOK

2026-08-21 09:00:00 Lytix Biopharma: Invitation to the Q2 2026 Results Presentation 7,50 NOK | 0,00% | 0,08 MNOK

2026-08-21 07:30:00 Lytix Biopharma: Invitation to the Q2 2026 Results Presentation 7,50 NOK | 0,00% | 0,08 MNOK

2026-08-18 10:35:57 Lytix Biopharma ASA: Lytix Biopharma Strengthens Business Development Leadership with Appointment of Timothy Herpin as Chief Business Officer 7,76 NOK | -3,00% | 0,36 MNOK

2026-08-18 10:30:14 LYTIX: Lytix Biopharma Strengthens Business Development Leadership with Appointment of Timothy Herpin as Chief Business Officer 7,76 NOK | -3,00% | 0,36 MNOK

2026-07-23 14:15:36 Lytix Biopharma ASA: Grant of share options to management and key personnel 9,26 NOK | 0,00% | 0,35 MNOK

2026-06-01 07:07:25 Lytix Biopharma ASA: Lytix Biopharma Reports Phase II Data in Melanoma and Triple-Negative Breast Cancer for Ruxotemitide (LTX-315) in Combination with Pembrolizumab 9,90 NOK | -6,16% | 1,20 MNOK

2026-06-01 07:05:12 LYTIX: Lytix Biopharma Reports Phase II Data in Melanoma and Triple-Negative Breast Cancer for Ruxotemitide (LTX-315) in Combination with Pembrolizumab 9,90 NOK | -6,16% | 1,20 MNOK

2026-05-21 07:05:00 Lytix Biopharma Q1 2026: Clinical Development Priorities On Track as Registrational Path Planning Advances 10,80 NOK | +4,85% | 0,30 MNOK

2026-05-21 07:00:00 Lytix Biopharma Q1 2026: Clinical Development Priorities On Track as Registrational Path Planning Advances 10,80 NOK | +4,85% | 0,30 MNOK

2026-05-15 10:23:00 Lytix Biopharma: Invitation to the Q1 2026 Results Presentation 10,80 NOK | +2,37% | 0,59 MNOK

2026-05-15 10:16:21 Lytix Biopharma: Invitation to the Q1 2026 Results Presentation 10,80 NOK | +2,37% | 0,59 MNOK

2026-05-06 07:05:00 Lytix Biopharma ASA: New Phase II Study Data from Lytix Biopharma's Partner Verrica Pharmaceuticals to be Presented at SID 2026 Highlight Potential Abscopal Effects of Ruxotemitide in Basal Cell Carcinoma 10,55 NOK | -0,47% | 1,54 MNOK

2026-05-06 07:00:00 LYTIX: New Phase II Study Data from Lytix Biopharma's Partner Verrica Pharmaceuticals to be Presented at SID 2026 Highlight Potential Abscopal Effects of Ruxotemitide in Basal Cell Carcinoma 10,55 NOK | -0,47% | 1,54 MNOK

2026-04-21 16:05:00 Lytix Biopharma ASA to Showcase Promising Phase II Results for Ruxotemitide Combination Therapy at ASCO 2026 9,90 NOK | -4,35% | 3,23 MNOK

2026-04-21 16:00:00 LYTIX: Lytix Biopharma ASA to Showcase Promising Phase II Results for Ruxotemitide Combination Therapy at ASCO 2026 9,90 NOK | -4,35% | 3,23 MNOK

2026-04-21 07:05:00 Lytix Biopharma ASA Reports Promising Final Phase II Results for Ruxotemitide (LTX-315) in Combination with Pembrolizumab in PD-1/PD-L1 Refractory Advanced Melanoma 9,90 NOK | -4,35% | 3,23 MNOK

2026-04-21 07:00:00 LYTIX: Lytix Biopharma ASA Reports Promising Final Phase II Results for Ruxotemitide (LTX-315) in Combination with Pembrolizumab in PD-1/PD-L1 Refractory Advanced Melanoma 9,90 NOK | -4,35% | 3,23 MNOK

2026-04-16 23:25:32 Lytix Biopharma ASA - Conversion to public limited liability company and name change registered 10,40 NOK | +1,46% | 0,62 MNOK

2026-04-16 23:18:30 Lytix Biopharma ASA - Conversion to public limited liability company and name change registered 10,40 NOK | +1,46% | 0,62 MNOK

2026-04-14 17:12:43 Lytix Biopharma AS: Minutes from Annual General Meeting 10,20 NOK | -1,92% | 0,56 MNOK

2026-04-14 17:07:43 Lytix Biopharma AS: Minutes from Annual General Meeting 10,20 NOK | -1,92% | 0,56 MNOK

2026-04-09 20:57:44 Lytix Biopharma AS: MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDER - GRANT OF SHARE OPTIONS 10,75 NOK | +3,86% | 2,30 MNOK

2026-04-09 20:52:20 Lytix Biopharma AS: MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDER - GRANT OF SHARE OPTIONS 10,75 NOK | +3,86% | 2,30 MNOK

2026-04-07 07:05:00 Lytix Biopharma AS: Lytix Biopharma Appoints Renée Christine Amundsen as Chief Operating Officer to Support Next Phase of Growth 10,35 NOK | -0,48% | 0,31 MNOK

2026-04-07 07:00:00 LYTIX: Lytix Biopharma Appoints Renée Christine Amundsen as Chief Operating Officer to Support Next Phase of Growth 10,35 NOK | -0,48% | 0,31 MNOK

2026-03-25 09:18:57 Lytix Biopharma AS: Notice of Annual General Meeting on 14 April 2026 10,25 NOK | 0,00% | 0,61 MNOK

2026-03-25 09:14:59 Lytix Biopharma AS: Notice of Annual General Meeting on 14 April 2026 10,25 NOK | 0,00% | 0,61 MNOK

2026-03-24 07:13:53 Lytix Biopharma AS: Annual Report for 2025 10,25 NOK | -0,49% | 0,43 MNOK

2026-03-24 07:03:54 Lytix Biopharma AS: Annual Report for 2025 10,25 NOK | -0,49% | 0,43 MNOK

2026-03-18 07:05:00 Lytix Biopharma AS: Lytix Biopharma to Present Final Phase II ATLAS-IT-05 Data at the AACR Annual Meeting 2026 10,80 NOK | +1,89% | 1,10 MNOK

2026-03-18 07:00:00 LYTIX: Lytix Biopharma to Present Final Phase II ATLAS-IT-05 Data at the AACR Annual Meeting 2026 10,80 NOK | +1,89% | 1,10 MNOK

2026-02-24 12:23:44 Lytix Biopharma AS - New share capital registered 9,24 NOK | 0,00% | 0,12 MNOK

2026-02-24 12:16:13 Lytix Biopharma AS - New share capital registered 9,24 NOK | 0,00% | 0,12 MNOK

2026-02-17 08:53:37 Lytix Biopharma AS: Lytix Biopharma Publishes Comprehensive Review on the Transformative Potential of Oncolytic Peptides in Leading Cancer Journal (JITC) 9,10 NOK | -1,09% | 0,18 MNOK

2026-02-17 08:49:29 LYTIX: Lytix Biopharma Publishes Comprehensive Review on the Transformative Potential of Oncolytic Peptides in Leading Cancer Journal (JITC) 9,10 NOK | -1,09% | 0,18 MNOK

2026-02-12 07:05:00 Lytix Biopharma AS: Lytix Biopharma: Q4 2025 Presentation and Publication of H2 2025 Interim Report 9,52 NOK | -0,42% | 1,21 MNOK

2026-02-12 07:00:00 Lytix Biopharma: Q4 2025 Presentation and Publication of H2 2025 Interim Report 9,52 NOK | -0,42% | 1,21 MNOK

2026-02-10 19:04:17 Lytix Biopharma AS - Final result of Subsequent Offering and allocation of Offer Shares 9,56 NOK | +1,92% | 1,00 MNOK

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode